Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXSFree Report) in a research report report published on Wednesday morning. The firm issued a sell rating on the stock.

Separately, LADENBURG THALM/SH SH upgraded Ayala Pharmaceuticals from a neutral rating to a buy rating in a research note on Tuesday, May 30th.

View Our Latest Report on Ayala Pharmaceuticals

Ayala Pharmaceuticals Trading Down 11.2 %

Ayala Pharmaceuticals stock opened at $0.88 on Wednesday. The firm has a market capitalization of $1.60 million, a P/E ratio of -0.10 and a beta of 2.34. The stock has a fifty day moving average price of $1.09 and a 200 day moving average price of $1.02. Ayala Pharmaceuticals has a 52 week low of $0.65 and a 52 week high of $3.75.

About Ayala Pharmaceuticals

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers.

Featured Stories

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.